COYA Coya Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835022 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.6%
TTM net income YoY-63.7%
TTM EPS YoY-25.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-675.3%
Net margin-643.5%
FCF margin—
EBITDA margin-675.0%
Returns
ROE-99.2%
ROA-84.6%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets14.6%
Debt / equity0.00x
Current ratio7.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-23.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $234,134 | $243,745 | $251,147 | $3.96M | $3.56M | $163,616 | $257,884 | $1,952 |
| R&D expense | $8.57M | $5.03M | $4.10M | $4.94M | $2.92M | $3.66M | $5.21M | $1.94M |
| SG&A expense | $2.59M | $2.26M | $3.78M | $3.27M | $2.56M | $2.91M | $2.71M | $2.14M |
| Operating income | -$10.95M | -$7.05M | -$7.64M | -$6.03M | -$2.43M | -$6.41M | -$7.68M | -$4.08M |
| Pretax income | -$10.62M | -$6.64M | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | — |
| Income tax | — | — | — | — | — | $0 | — | — |
| Net income | -$10.62M | -$6.64M | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -$2.92M |
| EBITDA | -$10.95M | -$7.04M | -$7.64M | -$6.02M | -$2.43M | -$6.41M | -$7.67M | -$4.07M |
| EPS (basic) | -0.45 | -0.28 | -0.32 | — | -0.13 | -0.36 | -0.44 | — |
| EPS (diluted) | -0.45 | -0.28 | -0.32 | — | -0.13 | -0.36 | -0.44 | — |
| Weighted avg. shares (diluted) | 23.46M | 23.46M | 22.64M | — | 16.73M | 16.72M | 16.72M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $35.80M | $43.18M | $50.72M | $46.82M | $28.13M | $29.76M | $35.53M | $38.34M |
| Current assets | $39.07M | $47.06M | $53.26M | $49.94M | $32.02M | $33.43M | $38.37M | $44.31M |
| PP&E, net | $2,807 | $5,614 | $8,420 | $11,227 | $18,068 | $24,908 | $31,748 | $38,588 |
| Total assets | $39.32M | $47.31M | $53.27M | $49.95M | $32.04M | $33.45M | $38.40M | $44.35M |
| Current liabilities | $5.39M | $3.51M | $3.55M | $5.87M | $3.67M | $4.50M | $4.34M | $3.82M |
| Total liabilities | $5.75M | $4.03M | $4.30M | $6.92M | $4.76M | $5.14M | $5.04M | $4.77M |
| Shareholders' equity | $33.57M | $43.28M | $48.97M | $43.03M | $27.28M | $28.31M | $33.37M | $39.58M |
| Shares outstanding | 23.46M | 23.46M | 23.46M | 20.93M | 16.74M | 16.72M | 16.72M | 16.71M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.24M | -$7.38M | -$6.21M | -$1.01M | -$1.13M | -$5.77M | -$2.83M | -$2.41M |
| Investing cash flow | -$23,240 | -$1,656 | -$885,000 | -$648,606 | — | — | — | $0 |
| Financing cash flow | -$120,441 | -$166,069 | $11.00M | $20.35M | $19,137 | $0 | $19,137 | $9.69M |
| Depreciation & amortization | $2,807 | $2,807 | $2,807 | $6,841 | $6,840 | $6,840 | $6,840 | $6,840 |
| Stock-based compensation | $910,076 | $943,911 | $2.20M | $1.10M | $1.07M | $1.04M | $1.08M | $790,549 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.